https://novapharmanews.com/us/news/lunai-bioworks-brainstorm-therapeutics-ai-collaboration 2026-05-31T04:46:04.362Z NovaPharmaNews en-US 2026-05-30T13:14:56.236Z Lunai Bioworks and BrainStorm Therapeutics Launch AI Collaboration for Parkinson's and Rare Epilepsy Parkinson's disease, Rare Epilepsy https://novapharmanews.com/uploads/articles/lunai-bioworks-brainstorm-therapeutics-ai-collaboration.webp Lunai Bioworks and BrainStorm Therapeutics Launch AI Collaboration for Parkinson's and Rare Epilepsy https://novapharmanews.com/eu/news/chmp-may-2026-output-shift-european-drug-development 2026-05-31T04:36:09.716Z NovaPharmaNews en-GB 2026-05-30T13:14:56.236Z CHMP May 2026 Output: A New Era in Drug Approvals https://novapharmanews.com/uploads/articles/chmp-may-2026-drug-approvals.webp CHMP May 2026 Output: A New Era in Drug Approvals https://novapharmanews.com/us/news/big-pharma-ma-spree-march-ipo-drought 2026-05-31T04:35:31.675Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Big Pharma's M&A Spree and the March IPO Drought: An Analysis https://novapharmanews.com/uploads/articles/big-pharma-ma-spree-march-ipo-drought.webp Big Pharma's M&A Spree and the March IPO Drought: An Analysis https://novapharmanews.com/us/news/regeneron-fda-approval-neurosensory-gene-therapy 2026-05-31T04:35:26.176Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Regeneron Secures FDA Approval for Pioneering Neurosensory Gene Therapy gene therapy https://novapharmanews.com/uploads/articles/regeneron-fda-approval-neurosensory-gene-therapy.webp Regeneron Secures FDA Approval for Pioneering Neurosensory Gene Therapy https://novapharmanews.com/us/news/pharma-ma-boom-2026-market-analysis 2026-05-31T05:19:59.222Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Pharma M&A Set to Boom in 2026: Market Analysis https://novapharmanews.com/uploads/articles/pharma-ma-boom-2026-market-analysis.webp Pharma M&A Set to Boom in 2026: Market Analysis https://novapharmanews.com/us/news/longeveron-stockholder-letter-corporate-strategy-2026-goals 2026-05-31T05:18:24.678Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Longeveron Stockholder Letter Highlights Corporate Strategy and 2026 Goals https://novapharmanews.com/uploads/articles/longeveron-stockholder-letter-corporate-strategy-2026-goals.webp Longeveron Stockholder Letter Highlights Corporate Strategy and 2026 Goals https://novapharmanews.com/us/news/ai-breast-cancer-risk-prediction-tool-fda-approval 2026-05-31T05:18:36.612Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z AI Breast Cancer Risk Prediction Tool Gains FDA Approval oncology, breast cancer https://novapharmanews.com/uploads/articles/ai-breast-cancer-risk-prediction-tool-fda-approval.webp AI Breast Cancer Risk Prediction Tool Gains FDA Approval https://novapharmanews.com/us/news/regulatory-actions-may-2026 2026-05-31T04:35:46.690Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Regulatory Actions in May 2026: Key Updates for Pharma https://novapharmanews.com/uploads/articles/regulatory-actions-may-2026.webp Regulatory Actions in May 2026: Key Updates for Pharma https://novapharmanews.com/us/news/states-confront-medical-chatbots-oversight-fda-inaction 2026-05-31T05:17:26.855Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z States Confront Medical Chatbots Oversight Amid FDA Inaction https://novapharmanews.com/uploads/articles/states-confront-medical-chatbots-oversight-fda-inaction.webp States Confront Medical Chatbots Oversight Amid FDA Inaction https://novapharmanews.com/us/news/pharmtech-regulatory-roundup-may-2026-drug-approvals 2026-05-31T04:35:24.183Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z PharmTech’s Regulatory Roundup for May 2026: Drug Approvals https://novapharmanews.com/uploads/articles/pharmtech-regulatory-roundup-may-2026-drug-approvals.webp PharmTech’s Regulatory Roundup for May 2026: Drug Approvals https://novapharmanews.com/us/news/bizengri-fda-national-priority-rare-bile-duct-cancer 2026-05-31T04:35:37.684Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Bizengri Receives FDA National Priority Nod for Rare Bile Duct Cancer Bizengri, rare bile duct cancer https://novapharmanews.com/uploads/articles/bizengri-fda-national-priority-rare-bile-duct-cancer.webp Bizengri Receives FDA National Priority Nod for Rare Bile Duct Cancer https://novapharmanews.com/us/news/vir-biotechnology-stock-board-reshuffle-governance-votes 2026-05-31T05:20:08.356Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Vir Biotechnology Stock: Board Reshuffle and Governance Votes Post-AGM https://novapharmanews.com/uploads/articles/vir-biotechnology-stock-board-reshuffle-governance-votes.webp Vir Biotechnology Stock: Board Reshuffle and Governance Votes Post-AGM https://novapharmanews.com/us/news/life-sciences-dealmaking-momentum-strategic-pressures 2026-05-31T05:16:51.002Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Life Sciences Dealmaking Gains Momentum Amid Strategic Pressures https://novapharmanews.com/uploads/articles/life-sciences-dealmaking-momentum-strategic-pressures.webp Life Sciences Dealmaking Gains Momentum Amid Strategic Pressures https://novapharmanews.com/us/news/fda-commissioner-resignation-drug-approvals 2026-05-31T05:16:58.403Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z FDA Commissioner Resignation and Its Impact on Drug Approvals https://novapharmanews.com/uploads/articles/fda-commissioner-resignation-drug-approvals.webp FDA Commissioner Resignation and Its Impact on Drug Approvals https://novapharmanews.com/us/news/big-pharma-biotech-assets-patent-cliff 2026-05-31T05:19:49.218Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Big Pharma's Race for Biotech Assets Amid $170 Billion Patent Cliff https://novapharmanews.com/uploads/articles/big-pharma-biotech-assets-patent-cliff.webp Big Pharma's Race for Biotech Assets Amid $170 Billion Patent Cliff https://novapharmanews.com/us/news/editas-medicine-inc-stock-quiet-trading-clinical-trials 2026-05-31T05:19:55.121Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Editas Medicine Inc Stock: Quiet Trading Ahead of Clinical Trials https://novapharmanews.com/uploads/articles/editas-medicine-inc-stock-quiet-trading-clinical-trials.webp Editas Medicine Inc Stock: Quiet Trading Ahead of Clinical Trials https://novapharmanews.com/us/news/pfizer-innovent-deal-global-drug-development-oncology 2026-05-31T05:20:20.555Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Pfizer-Innovent Deal: A New Model for Global Drug Development in Oncology oncology https://novapharmanews.com/uploads/articles/pfizer-innovent-deal-global-drug-development-oncology.webp Pfizer-Innovent Deal: A New Model for Global Drug Development in Oncology https://novapharmanews.com/us/news/ai-brain-organoids-parkinsons-rare-epilepsy-regulatory-updates 2026-05-31T04:35:49.198Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z AI and Brain Organoids Combat Parkinson's and Rare Epilepsy Parkinson's disease, Rare Epilepsy https://novapharmanews.com/uploads/articles/ai-brain-organoids-parkinsons-rare-epilepsy-regulatory-updates.webp AI and Brain Organoids Combat Parkinson's and Rare Epilepsy https://novapharmanews.com/apac/news/innovent-biologics-pfizer-10-5b-oncology-partnership 2026-05-31T05:23:31.790Z NovaPharmaNews en-AU 2026-05-30T13:14:36.494Z Innovent Biologics and Pfizer: A $10.5B Oncology Partnership oncology, cancer https://novapharmanews.com/uploads/articles/innovent-biologics-pfizer-10-5b-oncology-partnership.webp Innovent Biologics and Pfizer: A $10.5B Oncology Partnership https://novapharmanews.com/eu/news/imfinzi-fda-approval-bladder-cancer 2026-05-31T05:17:13.283Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z Imfinzi Receives FDA Approval for Bladder Cancer Treatment Imfinzi, oncology, bladder cancer https://novapharmanews.com/uploads/articles/imfinzi-fda-approval-bladder-cancer.webp Imfinzi Receives FDA Approval for Bladder Cancer Treatment https://novapharmanews.com/apac/news/premia-lind-ai-clinical-trial-screening-asia-pacific 2026-05-31T05:17:15.859Z NovaPharmaNews en-AU 2026-05-30T13:14:36.494Z PREMIA and Lind Expand AI-Powered Clinical Trial Screening Across Asia-Pacific https://novapharmanews.com/uploads/articles/premia-lind-ai-clinical-trial-screening-asia-pacific.webp PREMIA and Lind Expand AI-Powered Clinical Trial Screening Across Asia-Pacific https://novapharmanews.com/apac/news/onconic-therapeutics-jakubo-phase-3-clinical-trials-china 2026-05-31T05:17:21.602Z NovaPharmaNews en-AU 2026-05-30T13:14:36.494Z Onconic Therapeutics' Jakubo Enters Phase 3 Clinical Trials in China https://novapharmanews.com/uploads/articles/onconic-therapeutics-jakubo-phase-3-clinical-trials-china.webp Onconic Therapeutics' Jakubo Enters Phase 3 Clinical Trials in China https://novapharmanews.com/eu/news/merz-therapeutics-kvvit-inbrija-agreement 2026-05-31T05:17:31.515Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z Merz Therapeutics and Kvvit Enter Exclusive Agreement for INBRIJA® INBRIJA, levodopa https://novapharmanews.com/uploads/articles/merz-therapeutics-kvvit-inbrija-agreement.webp Merz Therapeutics and Kvvit Enter Exclusive Agreement for INBRIJA® https://novapharmanews.com/eu/news/italy-fourth-europe-clinical-research-enrollment 2026-05-31T05:17:39.686Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z Italy Ranks Fourth in Europe for Clinical Research but Lags in Enrollment Speed https://novapharmanews.com/uploads/articles/italy-fourth-europe-clinical-research-enrollment.webp Italy Ranks Fourth in Europe for Clinical Research but Lags in Enrollment Speed https://novapharmanews.com/eu/news/prac-meeting-highlights-may-2026 2026-05-31T05:17:42.445Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z PRAC Meeting Highlights: Regulatory Updates from May 2026 https://novapharmanews.com/uploads/articles/prac-meeting-highlights-may-2026.webp PRAC Meeting Highlights: Regulatory Updates from May 2026 https://novapharmanews.com/eu/news/2026-cell-therapy-regulatory-landscape 2026-05-31T05:18:15.387Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z Navigating the 2026 Cell Therapy Regulatory Landscape cell therapy https://novapharmanews.com/uploads/articles/2026-cell-therapy-regulatory-landscape.webp Navigating the 2026 Cell Therapy Regulatory Landscape https://novapharmanews.com/apac/news/cell-gene-therapy-approvals-china-regulatory-updates 2026-05-31T05:20:17.807Z NovaPharmaNews en-AU 2026-05-30T13:14:36.494Z Cell and Gene Therapy Approvals in China: Latest Regulatory Updates gene therapy https://novapharmanews.com/uploads/articles/cell-gene-therapy-approvals-china-regulatory-updates.webp Cell and Gene Therapy Approvals in China: Latest Regulatory Updates https://novapharmanews.com/eu/news/imfinzi-approval-bladder-cancer 2026-05-31T05:19:59.383Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z IMFINZI® Approved for High-Risk Bladder Cancer: A Game Changer durvalumab, Imfinzi, oncology, non-muscle-invasive bladder cancer https://novapharmanews.com/uploads/articles/imfinzi-approval-bladder-cancer.webp IMFINZI® Approved for High-Risk Bladder Cancer: A Game Changer https://novapharmanews.com/eu/news/critical-medicines-act-council-parliament-deal 2026-05-31T04:36:12.207Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z Critical Medicines Act: Council and Parliament Reach Provisional Deal https://novapharmanews.com/uploads/articles/critical-medicines-act-council-parliament-deal.webp Critical Medicines Act: Council and Parliament Reach Provisional Deal https://novapharmanews.com/apac/news/regulatory-round-up-drug-approvals-april-20-2026 2026-05-31T05:18:35.722Z NovaPharmaNews en-AU 2026-05-30T13:14:36.494Z Regulatory Round-Up: Drug Approvals on April 20, 2026 https://novapharmanews.com/uploads/articles/regulatory-round-up-drug-approvals-april-20-2026.webp Regulatory Round-Up: Drug Approvals on April 20, 2026 https://novapharmanews.com/eu/news/pfizer-innovent-105bn-adc-oncology-partnership 2026-05-31T04:36:21.225Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z Pfizer and Innovent Join Forces for $10.5bn ADC Oncology Partnership oncology https://novapharmanews.com/uploads/articles/pfizer-innovent-105bn-adc-oncology-partnership.webp Pfizer and Innovent Join Forces for $10.5bn ADC Oncology Partnership https://novapharmanews.com/apac/news/clinical-trials-market-oncology-2034 2026-05-31T05:17:24.795Z NovaPharmaNews en-AU 2026-05-30T13:14:36.494Z Clinical Trials Market in Oncology: Size and Growth Insights for 2034 oncology https://novapharmanews.com/uploads/articles/clinical-trials-market-oncology-2034.webp Clinical Trials Market in Oncology: Size and Growth Insights for 2034 https://novapharmanews.com/eu/news/esmo-2025-preview-astra-daiichi-gilead 2026-05-31T05:18:26.341Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z ESMO 2025 Preview: Astra and Daiichi vs. Gilead oncology https://novapharmanews.com/uploads/articles/esmo-2025-preview-astra-daiichi-gilead.webp ESMO 2025 Preview: Astra and Daiichi vs. Gilead https://novapharmanews.com/eu/news/pfizer-innovent-10-5bn-oncology-deal 2026-05-31T05:20:15.970Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z Pfizer and Innovent Biologics' $10.5bn Oncology Deal: What It Means oncology, cancer https://novapharmanews.com/uploads/articles/pfizer-innovent-10-5bn-oncology-deal.webp Pfizer and Innovent Biologics' $10.5bn Oncology Deal: What It Means https://novapharmanews.com/eu/news/pfizer-innovent-cancer-drug-alliance 2026-05-31T05:18:13.253Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z Pfizer and Innovent Form $10.5 Billion Cancer Drug Alliance oncology, cancer https://novapharmanews.com/uploads/articles/pfizer-innovent-cancer-drug-alliance.webp Pfizer and Innovent Form $10.5 Billion Cancer Drug Alliance